Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Average Rating of “Moderate Buy” from Analysts

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has been given a consensus recommendation of “Moderate Buy” by the nineteen research firms that are currently covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation, sixteen have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $187.39.

Several equities analysts recently commented on SRPT shares. Evercore ISI upgraded Sarepta Therapeutics from an “in-line” rating to an “outperform” rating and cut their target price for the stock from $185.00 to $179.00 in a research report on Thursday, August 8th. Citigroup lowered their target price on shares of Sarepta Therapeutics from $176.00 to $160.00 and set a “neutral” rating on the stock in a report on Thursday, August 8th. Leerink Partners boosted their price target on shares of Sarepta Therapeutics from $165.00 to $230.00 and gave the company an “outperform” rating in a research report on Monday, June 24th. Morgan Stanley reaffirmed an “overweight” rating and set a $165.00 price objective on shares of Sarepta Therapeutics in a research note on Friday, June 21st. Finally, Bank of America lifted their target price on shares of Sarepta Therapeutics from $166.00 to $213.00 and gave the company a “buy” rating in a research note on Friday, June 21st.

Sarepta Therapeutics Stock Performance

Shares of NASDAQ SRPT opened at $124.53 on Monday. The firm has a market capitalization of $11.77 billion, a price-to-earnings ratio of 1,132.09 and a beta of 0.81. Sarepta Therapeutics has a one year low of $55.25 and a one year high of $173.25. The business has a fifty day simple moving average of $134.99 and a 200 day simple moving average of $132.70. The company has a current ratio of 3.90, a quick ratio of 3.19 and a debt-to-equity ratio of 1.05.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported $0.07 EPS for the quarter, topping analysts’ consensus estimates of $0.01 by $0.06. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. The company had revenue of $362.90 million during the quarter, compared to the consensus estimate of $394.38 million. During the same period last year, the firm earned ($0.27) EPS. The firm’s revenue for the quarter was up 38.9% compared to the same quarter last year. Sell-side analysts expect that Sarepta Therapeutics will post 1.45 EPS for the current year.

Insider Buying and Selling

In other Sarepta Therapeutics news, CFO Ian Michael Estepan sold 5,985 shares of the stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $137.36, for a total value of $822,099.60. Following the transaction, the chief financial officer now owns 33,946 shares of the company’s stock, valued at $4,662,822.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, CFO Ian Michael Estepan sold 5,985 shares of the company’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $137.36, for a total value of $822,099.60. Following the completion of the sale, the chief financial officer now directly owns 33,946 shares of the company’s stock, valued at approximately $4,662,822.56. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Michael Andrew Chambers acquired 37,038 shares of Sarepta Therapeutics stock in a transaction that occurred on Friday, August 16th. The shares were purchased at an average cost of $133.80 per share, for a total transaction of $4,955,684.40. Following the purchase, the director now directly owns 284,034 shares in the company, valued at $38,003,749.20. The disclosure for this purchase can be found here. 7.70% of the stock is owned by insiders.

Institutional Trading of Sarepta Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Nordea Investment Management AB increased its holdings in shares of Sarepta Therapeutics by 120.6% in the first quarter. Nordea Investment Management AB now owns 61,657 shares of the biotechnology company’s stock worth $8,004,000 after acquiring an additional 33,711 shares in the last quarter. Capital Fund Management S.A. bought a new position in Sarepta Therapeutics in the fourth quarter valued at approximately $7,299,000. ADAR1 Capital Management LLC acquired a new position in shares of Sarepta Therapeutics in the fourth quarter valued at approximately $777,000. Fifth Third Wealth Advisors LLC bought a new stake in shares of Sarepta Therapeutics during the second quarter worth $607,000. Finally, Principal Financial Group Inc. raised its holdings in shares of Sarepta Therapeutics by 125.3% during the fourth quarter. Principal Financial Group Inc. now owns 49,539 shares of the biotechnology company’s stock worth $4,777,000 after acquiring an additional 27,549 shares during the period. Institutional investors and hedge funds own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.